FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Laura Shawver

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Physiology

Cell Divisions

Disorders

Neovascularization, Pathologic

Co-author Network

Publications

TOP 3
Deborah A Zajchowski; Beth Y Karlan; Laura K Shawver
Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas.
Qingling Zhang; Wyming Lee Pang; Hui Chen; Julie M Cherrington; Kenneth Lipson; Lida Antonian; Laura K Shawver
Application of LC/MS/MS in the quantitation of SU101 and SU0020 uptake by 3T3/PDGFr cells.
Laura K Shawver; Dennis J Slamon; Axel Ullrich
Smart drugs: tyrosine kinase inhibitors in cancer therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Laura Shawver (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Deborah A Zajchowski; Beth Y Karlan; Laura K Shawver
Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas.
Molecular cancer therapeutics 2012;11(2):492-502.
2002: Qingling Zhang; Wyming Lee Pang; Hui Chen; Julie M Cherrington; Kenneth Lipson; Lida Antonian; Laura K Shawver
Application of LC/MS/MS in the quantitation of SU101 and SU0020 uptake by 3T3/PDGFr cells.
Journal of pharmaceutical and biomedical analysis 2002;28(3-4):701-9.
2002: Laura K Shawver; Dennis J Slamon; Axel Ullrich
Smart drugs: tyrosine kinase inhibitors in cancer therapy.
Cancer cell 2002;1(2):117-23.
2001: Juthamas Sukbuntherng; G Cropp; Alison L Hannah; G S Wagner; Laura K Shawver; Lida Antonian
Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.
The Journal of pharmacy and pharmacology 2001;53(12):1629-36.
2000: Dirk B Mendel; Randall E Schreck; D C West; Guangmin Li; LM Strawn; S S Tanciongco; S Vasile; Laura K Shawver; Julie M Cherrington
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4848-58.
2000: Lida Antonian; H Zhang; C Yang; G Wagner; Laura K Shawver; M Shet; Brian W Ogilvie; Ajay Madan; Andrew Parkinson
Biotransformation of the anti-angiogenic compound SU5416.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(12):1505-12.
2000: A Douglas Laird; Peter Vajkoczy; Laura K Shawver; Andreas Thurnher; Congxin Liang; M Mohammadi; J Schlessinger; Axel Ullrich; Stevan Hubbard; Robert Blake; TA Fong; LM Strawn; Li Sun; Cho Tang; R Hawtin; F Tang; Narmada Shenoy; KP Hirth; Gerald McMahon
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Cancer research 2000;60(15):4152-60.
2000: LM Strawn; Fairooz Kabbinavar; D P Schwartz; E Mann; Laura K Shawver; Dennis J Slamon; Julie M Cherrington
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2931-40.
2000: Dirk B Mendel; A Douglas Laird; Beverly D Smolich; Robert Blake; Congxin Liang; Alison L Hannah; R M Shaheen; L M Ellis; Steven D Weitman; Laura K Shawver; Julie M Cherrington
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
Anti-cancer drug design 2000;15(1):29-41.
2000: Julie M Cherrington; LM Strawn; Laura K Shawver
New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.
Advances in cancer research 2000;79():1-38.
1999: Li Sun; N Tran; Congxin Liang; F Tang; A Rice; Randall E Schreck; K Waltz; Laura K Shawver; Gerald McMahon; Cho Tang
Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
Journal of medicinal chemistry 1999;42(25):5120-30.
1999: T J Powell; Hannah Ben-Bassat; Benjamin Y Klein; Hui Chen; N Shenoy; J McCollough; B Narog; Aviv Gazit; Z Harzstark; Malka Chaouat; Rubina Levitzki; Cho Tang; J McMahon; Laura K Shawver; Alexander Levitzki
Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors.
The British journal of dermatology 1999;141(5):802-10.
1999: TA Fong; Laura K Shawver; Li Sun; Cho Tang; H App; T J Powell; Y H Kim; Randall E Schreck; Xueyan Wang; W Risau; Axel Ullrich; KP Hirth; Gerald McMahon
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Cancer research 1999;59(1):99-106.
1998: LM Strawn; Laura K Shawver
Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.
Expert opinion on investigational drugs 1998;7(4):553-73.
1997: Laura K Shawver; D P Schwartz; E Mann; Hui Chen; J Tsai; L Chu; L Taylorson; M Longhi; S Meredith; L Germain; J S Jacobs; Cho Tang; Axel Ullrich; Michael Berens; Evan M Hersh; Gerald McMahon; KP Hirth; T J Powell
Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(7):1167-77.
1996: L M Strawn; Gerald McMahon; H App; Randall E Schreck; W R Kuchler; M P Longhi; T H Hui; Cho Tang; Alexander Levitzki; Aviv Gazit; I Chen; G Keri; László Őrfi; Werner Risau; Ingo Flamme; A Ullrich; KP Hirth; Laura K Shawver
Flk-1 as a target for tumor growth inhibition.
Cancer research 1996;56(15):3540-5.
1996: B Millauer; M P Longhi; Karl H Plate; Laura K Shawver; Werner Risau; A Ullrich; L M Strawn
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
Cancer research 1996;56(7):1615-20.
1995: Laura K Shawver; L M Strawn; A Ullrich
Membrane bound receptor tyrosine kinases and chemical carcinogenesis.
Mutation research 1995;333(1-2):23-8.
1995: H L Liu; D L Parkes; B C Langton; J A Xuan; M Longhi; S S Elliger; L A Chao; M P McGrogan; J W Brandis; Laura K Shawver
Construction of a chimeric antibody with therapeutic potential for cancers which overexpress c-erbB-2.
Biochemical and biophysical research communications 1995;211(3):792-803.
1995: T J Powell; Randall E Schreck; M McCall; T Hui; A Rice; H App; M Azam; A Ullrich; Laura K Shawver
A tumor-derived protein which provides T-cell costimulation through accessory cell activation.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(4):209-21.
1994: L M Strawn; E Mann; S S Elliger; L M Chu; L L Germain; G Niederfellner; A Ullrich; Laura K Shawver
Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor.
The Journal of biological chemistry 1994;269(33):21215-22.
1994: Carlos L Arteaga; A R Winnier; M C Poirier; D M Lopez-Larraza; Laura K Shawver; S D Hurd; S J Stewart
p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Cancer research 1994;54(14):3758-65.
1994: Laura K Shawver; E Mann; S S Elliger; Teresa C Dugger; Carlos L Arteaga
Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
Cancer research 1994;54(5):1367-73.
1994: B Millauer; Laura K Shawver; Karl H Plate; Werner Risau; A Ullrich
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.
Nature 1994;367(6463):576-9.
1991: M C Hancock; B C Langton; T Chan; P Toy; J J Monahan; R P Mischak; Laura K Shawver
A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.
Cancer research 1991;51(17):4575-80.